Dr. Shivaani Kummar is Interim CEO, Knight Cancer Institute, Margaret and Lester DeArmond Chair of Molecular Oncology, Division Chief of Hematology and Medical Oncology, co-Director of the Center of Experimental Therapeutics, Knight Cancer Institute, Oregon Health & Science University (OHSU), Portland, Oregon, USA. Prior to joining OHSU in 2020, she was on faculty at Yale University Cancer Center (2000-2004), served as Head, Developmental Therapeutics Clinic, National Cancer Institute, NIH (2004-2011), Head of Early Clinical Trials Development Office of the
Director, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH
(2011-2015), Professor of Medicine and Director of the Phase 1 Clinical Research
Program and Translational Oncology Program at Stanford University, Palo Alto,
California (2015-2020). She specializes in conducting pharmacokinetic and
pharmacodynamic driven first-in-human trials tailored to make early, informed
decisions regarding the suitability of novel molecular agents for further clinical
investigation. She is a member of scientific planning committees of national and
international professional organizations and has authored over 180 peer reviewed
publications, 9 book chapters, and co-edited a book on ‘Novel Designs of Early Phase
Trials for Cancer Therapies’. She is a member of scientific planning committees of
national and international professional organizations and has authored over 180 peer
reviewed publications, 9 book chapters, and co-edited a book on ‘Novel Designs of
Early Phase Trials for Cancer Therapies’. She is currently a member of the Scientific
Planning Committee, American Society of Clinical Oncology (ASCO) 2025-2028),
Member, American Association for Cancer Research (AACR) Exploratory
IND/Phase 0 Clinical Trials Task Force (2021-Present), Scientific Planning
Committee, AACR (2025), and has served as Co-chair, AACR Annual Meeting
Clinical Trials Committee (2022-2024), Vice Chair AACR Annual Meeting 2023
Program Committee (2022-2023), Member, Developmental Therapeutics Scientific
Committee, Targeted Anticancer Therapies (TAT), European Society of Medical
Oncology (ESMO) Annual Meeting 2023 (2022-2023), Member, Scientific Planning
Committee, ESMO Annual Meeting 2023 (2022-2023)